EWTX News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

EW

Mkt Cap

$4.04B

Volume

961.79K

Next Earnings

November 5th

Loading chart

EW

EWTXEdgewise Therapeutics, Inc. Common Stock

EWTX

Pay with—

Available Balance0.00

EW

Mkt Cap

$4.15B

Volume

961.78K

Next Earnings

November 5th

Chart Financials Earnings News About Insider Filings

Will Camzyos' Long-Term Benefits Strengthen BMY's Growth Outlook?Bristol Myers Squibb's Camzyos demonstrated durable reductions in LVOT obstruction over five years with 97.4% of patients achieving target gradients. Sales surged 74% year-over-year to $729 million in H1 2026. The company seeks FDA approval for adolescents with a decision expected by September 30, 2026. However, competition is intensifying with Cytokinetics' Myqorzo approved in December 2025 and Edgewise Therapeutics advancing EDG-7500 in clinical trials.Zacks Investment Research · Sep 4, 2026

Can CYTK's Aficamten Strengthen Its HCM Growth Prospects?Cytokinetics announced additional positive results from ACACIA-HCM and MAPLE-HCM studies showing aficamten improved cardiac structure and diastolic function in non-obstructive HCM patients, and outperformed metoprolol in obstructive HCM. The company plans to file for nHCM approval in Q4 2026, potentially expanding the drug's addressable market. Myqorzo received FDA approval in December 2025 for obstructive HCM treatment.Zacks Investment Research · Sep 2, 2026

Immutrin appoints leading cardiovascular drug development expert Dr. Robert Blaustein as Chief Medical Officer and establishes US subsidiaryImmutrin Ltd, a biotechnology company developing antibody therapy for amyloidosis, has appointed Dr. Robert Blaustein as Chief Medical Officer. Blaustein brings over 15 years of cardiovascular drug development experience from previous roles at Edgewise Therapeutics and Merck. The company has also established a US subsidiary to support planned clinical activities in North America as it advances toward first-in-human studies.GlobeNewswire Inc. · May 6, 2026

Why Edgewise Therapeutics Stock Topped the Market on TuesdayEdgewise Therapeutics stock rose 2.18% on Tuesday after JPMorgan analyst Tessa Romero raised her price target by $11 per share to $45, maintaining an overweight rating. The upgrade was driven by optimism about the company's pipeline drugs, particularly EDG-7500 for heart disorder treatment and sevasemten for muscular dystrophy, which showed positive long-term study data.The Motley Fool · Mar 17, 2026

The $3B Biotech With Two Shots On GoalEdgewise Therapeutics, a $3.1B biotech company, has two major drug candidates with significant market potential. EDG-7500 for hypertrophic cardiomyopathy uses a novel mechanism (promoting heart relaxation) with superior safety profile compared to existing treatments, with efficacy data expected by June 2026. Sevasemten targets Becker Muscular Dystrophy, a disease with zero approved treatments, with pivotal trial results expected Q4 2026. The stock has tripled from its 52-week low and faces two binary catalysts this year.Benzinga · Mar 17, 2026

Why Edgewise Therapeutics Stock Crushed the Market on MondayEdgewise Therapeutics stock surged 4% on Monday after analyst Yasmeen Rahimi from Piper Sandler reiterated an overweight recommendation with a $51 price target. Rahimi flagged the biotech as one of Piper Sandler's best stock ideas for 2026, citing strong potential for its lead cardiovascular drug candidate EDG-7500 for treating hypertrophic cardiomyopathy, with Phase 2 results expected in Q2 2026. The company also has other promising pipeline programs including Sevasemten for muscular dystrophy.The Motley Fool · Feb 10, 2026

Why Edgewise Therapeutics Stock Rocked the Market TodayEdgewise Therapeutics stock surged nearly 26% on December 23rd after the biotech presented positive interim Phase 2 clinical trial data for EDG-7500, an investigational drug targeting hypertrophic cardiomyopathy (HCM). The drug showed clinical activity across significant disease markers, maintained a favorable safety profile, and exceeded year-end enrollment goals with over 70% of participants reaching the target 100mg dose. However, the author notes the drug still has distance to go before potential regulatory approval.The Motley Fool · Dec 24, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTXPomerantz Law Firm is investigating potential securities fraud by Edgewise Therapeutics after the company reported clinical trial results that were deemed insufficient for accelerated FDA approval, causing a stock price drop.GlobeNewswire Inc. · Aug 17, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTXPomerantz Law Firm is investigating potential securities fraud at Edgewise Therapeutics after the company reported clinical trial results that were deemed insufficient for accelerated FDA approval, causing a stock price drop.GlobeNewswire Inc. · Aug 9, 2025

Edgewise Therapeutics Soars 50%: Key Reasons Behind the SurgeEdgewise Therapeutics' (EWTX) share price surged 50% in a single session due to positive results from early trials of its novel treatment for obstructive hypertrophic cardiomyopathy, a leading cause of sudden cardiac-related death in young people. The company's pipeline and strong financial position also contribute to the positive sentiment.Benzinga · Sep 25, 2024

to start trading

EW

EWTXEdgewise Therapeutics, Inc. Common Stock

EWTX

Pay with—

Available Balance0.00

Your PositionYou don't own any EWTX yet.

Related Tickers

Earnings